Europe
Motif Bio plc announced today that the Company will participate in the following event
Selvita will publish the most recent data from its oncology programs at the 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC), which will take place on November 7–11, 2018 at the Walter E. Washington Convention Center in Washington, D.C., USA.
Medigene AG today announced its participation at the following upcoming investor and scientific conferences:
Vivek Ramaswamy’s Roivant Sciences, the umbrella company to 14 Vant companies, including Datavant, Enzyvant Sciences, Urovant Sciences and others, raised another $200 million in equity financing.
£100K grant will fund proof-of-concept studies to optimise bioprocessing of gene therapy vectors using hydrodynamic fluid flow fields
On Friday, the FDA approved Merck’s Keytruda, an anti-PD-1 therapy, for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with the chemotherapy drug sorafenib.
Clinical data for a fish-oil-based drug from Amarin Corporation PLC confirmed the drug’s ability to reduce the relative risk reduction of adverse cardiovascular events by 25 percent, including a 20 percent reduction in cardiovascular death.
InflaRx N.V. today announced that the first patient has been dosed in a phase II study to determine the safety and efficacy of IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients with ANCA-associated vasculitis (AAV).
Provepharm Life Solutions and partner Walter Reed Army Institute of Research were selected for project focusing on anti-malaria treatment in endemic regions
Microbiotica today announced that it will join the microbiome panel at this year’s BIO-Europe®, taking place in Copenhagen between 5-7 November.
PRESS RELEASES